Presenilin 1 – Cytoplasmic Linker Protein 170 interaction (PSEN1-CLIP170 interaction)

The interaction between Presenilin 1 (PSEN1) and Cytoplasmic Linker Protein 170 (CLIP-170, also known as Restin) is a critical regulatory mechanism in the pathogenesis of Alzheimer's disease. PSEN1, the catalytic subunit of the gamma-secretase complex, acts as an anchor that links subcellular vesicles containing amyloid precursor protein (APP) to microtubules via its binding to the C-terminal domain of CLIP-170 [24, 25]. This physical association facilitates the transport and spatial positioning of APP for proteolytic processing into amyloid-beta (Aβ) peptides [21, 24]. Research indicates that disrupting this specific protein-protein interaction using binding domain peptides (BDPs) can significantly reduce the production and secretion of neurotoxic Aβ42 [24]. Notably, this modulation appears to spare the cleavage of other gamma-secretase substrates like Notch, offering a potential therapeutic advantage over broad-spectrum gamma-secretase inhibitors [24]. Beyond APP processing, the PSEN1-CLIP170 complex is involved in microtubule dynamics and chromosome segregation, with mutations in PSEN1 potentially leading to aneuploidy [21]. Therapeutic strategies targeting this interaction aim to provide a more selective approach to treating neurodegeneration by specifically interfering with the amyloidogenic pathway [24, 30].

Other names

PS1-CLIP-170 interactionPresenilin-1/Restin complexPS1-CLIP170 complexPresenilin-1 – CLIP1 interaction

Disruption of the physical anchoring of APP-containing vesicles to microtubules, thereby selectively reducing gamma-secretase-mediated production of amyloid-beta while sparing Notch signaling.